The histone modifier genes KMT2C and KMT2D were identified as the most frequently mutated in AITL and PTCL-NOS [93] This study also indicated that the combination of chidamide and decitabine enhances the interaction of KMT2D with the transcription factor PU.1, inactivating the H3K4me-associated signalling pathway MAPK [94], which is constitutively activated in T-cell lymphoma [12, 95, 96]. Here, KMT2D is linked to mature T-cell and NK-cell non-Hodgkin lymphoma.